TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.【JP:E25678】

Market cap

P/E ratio

Summary Financials Dividends History Workforce

	Mar 31, 2013	Mar 31, 2014	Mar 31, 2015	Mar 31, 2016	Mar 31, 2017	Mar 31, 2018	Mar 31, 2019	Mar 31, 2020	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023
Net sales	285,168	295,957	290,498	290,135	279,773	280,092	261,551	288,527	281,980	268,203	301,381
Cost of sales	108,904	111,275	112,240	113,143	101,525	97,154	91,206	108,386	106,050	104,371	123,531
Operating expenses	140,873	143,009	146,273	147,935	146,260	146,007	138,951	158,923	156,021	153,088	154,831
Gross profit (loss)	176,264	184,682	178,258	176,991	178,248	182,938	170,345	180,190	175,929	163,831	177,850
Operating profit (loss)	35,337	41,683	31,974	28,878	31,966	36,977	31,211	21,460	19,965	10,743	23,018
Selling, general and administrative expenses	140,873	143,009	146,273	147,935	146,260	146,007	138,951	159,196	156,021	153,088	154,831
Interest income	5,326	5,296	5,373	5,392	5,134	4,999	4,952	3,769	1,690	1,338	1,592
Dividend income	1,119	1,202	1,317	1,439	1,604	1,723	1,897	1,990	1,928	2,110	2,239
Share of profit of entities accounted for using equity method	1,590	2,473	255	382	-	-	1,689	272	276	305	314
Non-operating income	9,011	9,700	7,788	8,068	7,511	7,479	9,774	6,619	6,483	8,478	7,817
Foreign exchange gains	-	-	-	-	-	-	-	-	1,958	4,221	3,154
Other	976	728	841	854	772	756	1,235	586	629	501	516
Non-operating income	9,011	9,700	7,788	8,068	7,511	7,479	9,774	6,619	6,483	8,478	7,817
Operating profit (loss)	35,337	41,683	31,974	28,878	31,966	36,977	31,211	21,460	19,965	10,743	23,018
Interest expenses	17	2	2	2	1	2	2	118	156	170	169
Commission expenses	111	106	92	106	91	94	84	81	82	111	87
Commission expenses	111	106	92	106	91	94	84	81	82	111	87
Non-operating expenses	175	140	186	170	1,441	2,316	135	3,282	502	808	391
Loss on investments in investment partnerships	-	-	-	-	-	-	-	21	51	-	26
Subsidiary stock acquisition-related cost	-	-	-	-	-	-	-	-	-	325	-
Other	46	31	91	62	75	28	48	335	212	201	107
Non-operating expenses	175	140	186	170	1,441	2,316	135	3,282	502	808	391
Interest income	5,326	5,296	5,373	5,392	5,134	4,999	4,952	3,769	1,690	1,338	1,592
Dividend income	1,119	1,202	1,317	1,439	1,604	1,723	1,897	1,990	1,928	2,110	2,239
Share of profit of entities accounted for using equity method	1,590	2,473	255	382	-	-	1,689	272	276	305	314
Non-operating income	9,011	9,700	7,788	8,068	7,511	7,479	9,774	6,619	6,483	8,478	7,817
Foreign exchange gains	-	-	-	-	-	-	-	-	1,958	4,221	3,154
Other	976	728	841	854	772	756	1,235	586	629	501	516
Non-operating income	9,011	9,700	7,788	8,068	7,511	7,479	9,774	6,619	6,483	8,478	7,817
Ordinary profit (loss)	44,173	51,244	39,576	36,775	38,036	42,140	40,851	25,010	25,946	18,412	30,444
Interest expenses	17	2	2	2	1	2	2	118	156	170	169
Commission expenses	111	106	92	106	91	94	84	81	82	111	87
Commission expenses	111	106	92	106	91	94	84	81	82	111	87
Non-operating expenses	175	140	186	170	1,441	2,316	135	3,282	502	808	391
Loss on investments in investment partnerships	-	-	-	-	-	-	-	21	51	-	26
Subsidiary stock acquisition-related cost	-	-	-	-	-	-	-	-	-	325	-
Other	46	31	91	62	75	28	48	335	212	201	107
Non-operating expenses	175	140	186	170	1,441	2,316	135	3,282	502	808	391
Gain on sale of non-current assets	1,606	120	1,035	19	14	619	37	39	19	11	90
Gain on sale of investment securities	-	56	-	-	4,123	5,598	-	-	5	4,069	1
Gain on sale of investment securities	-	56	-	-	4,123	5,598	-	-	5	4,069	1
Extraordinary income	1,606	177	1,035	19	4,138	6,218	42,982	6,133	24	4,119	891
Gain on sale of shares of subsidiaries and associates	-	-	-	-	-	-	42,944	-	-	-	800
Gain on reversal of share acquisition rights	-	-	-	-	-	-	-	-	-	38	-
Extraordinary income	1,606	177	1,035	19	4,138	6,218	42,982	6,133	24	4,119	891
Ordinary profit (loss)	44,173	51,244	39,576	36,775	38,036	42,140	40,851	25,010	25,946	18,412	30,444
Profit (loss) before income taxes	43,208	51,316	40,162	35,809	41,956	48,070	64,484	30,311	22,976	21,398	29,498
Gain on sale of non-current assets	1,606	120	1,035	19	14	619	37	39	19	11	90
Gain on sale of investment securities	-	56	-	-	4,123	5,598	-	-	5	4,069	1
Gain on sale of investment securities	-	56	-	-	4,123	5,598	-	-	5	4,069	1
Extraordinary income	1,606	177	1,035	19	4,138	6,218	42,982	6,133	24	4,119	891
Gain on sale of shares of subsidiaries and associates	-	-	-	-	-	-	42,944	-	-	-	800
Gain on reversal of share acquisition rights	-	-	-	-	-	-	-	-	-	38	-
Extraordinary income	1,606	177	1,035	19	4,138	6,218	42,982	6,133	24	4,119	891
Income taxes - current	11,461	17,662	12,075	11,828	11,494	14,522	14,989	10,042	8,460	8,582	6,936
Loss on disposal of non-current assets	239	105	396	134	184	288	80	240	518	143	270
Loss on sale of investment securities	-	-	-	-	33	-	-	-	72	-	-
Loss on valuation of investment securities	2,199	-	-	-	-	-	-	-	152	720	1,501
Impairment losses	-	-	-	850	-	-	2,916	592	2,250	269	65
Extraordinary losses	2,571	105	448	985	217	288	19,349	832	2,994	1,134	1,837
Income taxes - deferred	4,169	-356	2,027	99	255	179	-330	-1,618	-678	-2,134	1,259
Profit (loss) before income taxes	43,208	51,316	40,162	35,809	41,956	48,070	64,484	30,311	22,976	21,398	29,498
Income taxes	15,630	17,305	14,102	11,927	11,750	14,701	14,658	8,423	7,782	6,448	8,196
Income taxes - current	11,461	17,662	12,075	11,828	11,494	14,522	14,989	10,042	8,460	8,582	6,936
Profit (loss)	-	-	26,060	23,882	30,205	33,368	49,825	21,887	15,194	14,950	21,302
Income taxes - deferred	4,169	-356	2,027	99	255	179	-330	-1,618	-678	-2,134	1,259
Income taxes	15,630	17,305	14,102	11,927	11,750	14,701	14,658	8,423	7,782	6,448	8,196
Profit (loss)	-	-	26,060	23,882	30,205	33,368	49,825	21,887	15,194	14,950	21,302
Profit (loss) attributable to non-controlling interests	-	-	1,531	1,408	1,424	1,689	1,231	1,356	1,878	1,828	2,305
Profit (loss) attributable to owners of parent	-	-	24,528	22,473	28,781	31,679	48,593	20,531	13,316	13,122	18,997